the LV chamber in response to hemodynamic overload, a main role has been also attributed to the secretion of several cytokines and growth factors. 3, 4 For example, it has been shown that cytokines typically upregulated during transverse aortic constriction (TAC), such as interleukin-6 and tumor necrosis factor-␣ (TNF-␣), have key roles in cardiac hypertrophy and protective effects during the maladaptive transition to heart failure. 4, 5 Additionally, among the growth factors, the angiogenic ones seem to play a not trivial supportive role, besides inducing vessel growth, by contributing to the adaptation of cardiac muscle to hemodynamic overload. For example, defects in cardiac vascular endothelial growth factor (VEGF) impair the adaptive remodeling in overloaded hearts, accelerating the transition to heart failure. 6 Interestingly, the impact of a VEGF-related homolog, placental growth factor (PlGF), which shares properties of both angiogenic factor and cytokine, on cardiac remodeling induced by hemodynamic overload is still poorly explored. Expressed in cardiac tissue, PlGF increases in hypoxic/ischemic myocardium, 7 contributes to pathological angiogenesis, such as vascular regeneration under tissue ischemia, 8 and may have both positive or negative effects on tumor growth, 9, 10 suggesting that its environment can influence its effects. On the other hand, it has been demonstrated that the cytokine face of PlGF acts as a chemotactic agent for monocytes. 11, 12 It is well known that monocytes participate in the cardiac inflammatory response to pressure overload and support adaptive cardiac remodeling. 13 Moreover, TNF-␣ activation, one of the earliest inflammatory events in overloaded hearts, 5 has recently been linked to PlGF to recruit myelomonocytic cells in inflamed tissues. 14 In fact, TNF-␣ needs to be shed from a membrane-bound form by TNF-␣-converting enzyme (TACE), and the main natural inhibitor of TACE is tissue inhibitor of metalloproteinases-3 (TIMP-3), the most abundant TIMP expressed in cardiac tissue. 15 Interestingly, the lack of TIMP-3, producing excessive TNF-␣ activation, 16 promotes maladaptive cardiac remodeling, favoring the transition to heart failure. On the other hand, anti-TNF-␣ therapy fails to be successful for heart failure treatment, 17, 18 thus suggesting that, even if excessive inflammatory responses are detrimental, impaired inflammation also could be harmful, hampering an adequate tissue response to injury. Thus, PlGF has several features that could make it a candidate to play a role in the complex cytoarchitectural response of the heart to hemodynamic overload.
In this study, we explored the pathophysiological role of PlGF in cardiac remodeling to pressure overload as both an angiogenic factor and a cytokine. We clarify that PlGF is increased in overloaded hearts and that, in this context, it influences mainly vessel dimensions. More important, we identify that PlGF finely tunes a balanced regulation of the TIMP-3/TACE axis and the consequent TNF-␣ activation in response to TAC, thus ensuring an adequate inflammatory milieu for adaptive cardiac hypertrophic remodeling.
Methods
The detailed methodology is provided in the online-only Data Supplement.
Animals and Surgery
Experiments were conducted according to European Communities Council Directive No. 86/609/EEC in 12-to 15-week-old C57Bl/6J and PlGF knockout (KO)/wild-type (WT) male mice. Transverse aortic constriction was obtained as previously described. 19 
Drug Treatment and siRNA Studies
TAPI-I (Peptides International) was administered daily by subcutaneous injection. Negative control, TIMP-3, and FITCconjugated siRNA were synthesized by Santa Cruz and systemically injected. Recombinant PlGF (1.5 g/kg body weight; R&D Systems) was administered daily by intraperitoneal injection starting 2 days before TAC.
Echocardiographic Analysis
Echocardiographic analysis was performed with Vevo770 and Vevo2100 (Visualsonics Inc).
Immunohistochemistry, Histology, and In Situ Hybridization
For immunohistochemical, histological, and in situ hybridization analyses, hearts were removed after diastolic arrest, postfixed, and cryosectioned.
RNA, Reverse Transcription, Quantitative Polymerase Chain Reaction, and Polymerase Chain Reaction Array
TRIzol reagent for RNA extraction and Superscript III kit (Invitrogen, Eugene, OR) for cDNA preparing, SYBR green polymerase chain reaction master mix, and mouse polymerase chain reaction Array (PAMM-013, SABiosciences) were used according to the manufacturers' instructions.
Western Blotting and Gelatin Zymography
Heart proteins were extracted and resolved by SDS-PAGE, followed by Western blotting or gelatin zymography, as described in the online-only Data Supplement.
Tumor Necrosis Factor-␣ and Tumor Necrosis Factor-␣-Converting Enzyme Activity
The TNF-␣ levels and TACE activity were measured with a high-sensitivity ELISA kit (Endogen, Pierce) and an ␣-secretase activity kit (Anaspec), respectively.
Statistical Analysis
Echocardiographic analyses were tested with repeated measures 2-way ANOVA and the Bonferroni post hoc test; data are presented as meanϮSEM. Statistical significance of nonrepeated measures was calculated with 1-way ANOVA and the Bonferroni post hoc test when the sample size was Ն6 (data presented as meanϮSEM) and with the Kruskal-Wallis test with Dunn post hoc tests for sample sizes Ͻ6 (data presented as actual points). For 2-group comparisons, the Mann-Whitney test was applied. Statistical analyses were performed with GraphPad software PRISM5 (GraphPad Software Inc, La Jolla, CA).
Results

Placental Growth Factor Is Upregulated During Transverse Aortic Constriction, and Its Absence Accelerates Transition Toward Dilated Cardiomyopathy
Here, we show a time-dependent increase in cardiac PlGF in C57BL/6J mice exposed to TAC for 1 day and 1 week ( Figure  1A) . To explore the role of PlGF activation in pressure overload, we used echocardiography to follow up over time (1 to 2 to 4 weeks) PlGF KO and WT mice subjected to TAC.
The degree of aortic impedance imposed, ie, the trans-stenotic gradient, was similar in both genotypes ( Table I in the  online-only Data Supplement) . Notably, although WT developed a typical concentric hypertrophy, as evidenced by increased relative wall thickness ( Figure 1B and Table I in the online-only Data Supplement) and reduced LV internal diameter ( Figure 1C and Table I in the online-only Data Supplement), PlGF KO displayed impaired hypertrophy and early dilated cardiomyopathy ( Figure 1B and 1C and Table I in the online-only Data Supplement). In addition, cardiac fractional shortening (fractional shortening) in PlGF KO was significantly decreased at 1-week TAC compared with WT, with a further significant decline over time ( Figure 1D and Table I in the online-only Data Supplement).
To better characterize the myocardial performance of KO compared with WT, another group of mice were followed up for a longer period of time (until 6 weeks). Further deterioration of cardiac function and structure was observed in KO, as shown by both conventional ( Table II in the online-only Data Supplement) and speckle-trackingbased strain echocardiography ( Table III in the online-only Data Supplement) along the longitudinal and radial axes ( Figure 1E and 1F). In particular, myocardial tissue deformation, evaluated as the percent change in both strain and strain rate values of TAC versus sham, was significantly reduced in KO ( Figure 1E and 1F ). Displacement and velocity were also significantly reduced in KO after TAC ( Figure 1E and 1F). At 6 weeks from TAC, KO showed an increased mortality compared with WT, which was further aggravated at 8 weeks ( Figure 
Placental Growth Factor Knockout Mice Show Impaired Cardiomyocyte Growth and Increased Vessel Dimensions in Response to Transverse Aortic Constriction
We looked at the response of cardiomyocytes and vessels, 2 major components of TAC-induced cardiac remodeling. Histological analysis of 1-week TAC indicated that KO displayed a defect in the typical cardiomyocyte growth showed by WT (Figure 2A Because cardiomyocytes express PlGF receptor, VEGF receptor-1 (VEGFR-1), 21 we explored possible direct effects of PlGF on cardiomyocyte growth by stimulating isolated cardiomyocytes with increasing doses of recombinant PlGF. No direct evidence of hypertrophic growth, elicited by PlGF, was detected ( Figure IIB in the online-only Data Supplement), thus suggesting that the impaired hypertrophic response in overloaded KO hearts could not be ascribed to PlGF direct effects on muscle growth.
In terms of capillary status, overloaded WT LV showed a reduction in myocardial microvascular density ( Figure 2F and 2G), as indicated by the absolute number of vessels per area, but the capillary/myocyte ratio (Figure 2A and 2C) was in turn increased. However, although KO displayed a reduction in the capillary density in the myocardium ( Figure 2F and 2G) comparable to that of WT, their capillary/myocyte ratio in response to TAC remained unchanged (Figure 2A and 2C). Interestingly, KO showed a significant increase in vessel dimensions ( Figure 2F ), as evidenced by vessel area quantification ( Figure 2H ). To better characterize the impact of this particular vascular remodeling in KO during TAC, we performed an ultrasonographic tissue perfusion analysis by using microbubble contrast agent. We preserved KO by decreasing the LV myocardial flow observed after 1 week of TAC in WT ( Figure IIC in the online-only Data Supplement), indicating that the lack of PlGF, increasing microvessel dimensions, compensates for the microvascular rarefaction induced by TAC. Strikingly, although 1-week TAC WT showed activated hypoxia-inducible factor-1␣ ( Figure IID and IIE in the online-only Data Supplement), a typical signaling recruited by ischemic conditions, and accumulated hypoxic metabolites, as evidenced by hypoxyprobe staining ( Figure IIE in the online-only Data Supplement), KO mice did not display activation of any of them, thus suggesting that their micro-vascular remodeling preserves them from the typical myocardial ischemia accompanying TAC. More important, this particular vascular phenotype of KO cannot obviously explain their accelerated transition to heart failure.
Absence of Left Ventricular Fibrosis and Impaired Inflammation in Placental Growth Factor Knockout Mice in Response to Transverse Aortic Constriction
We then evaluated the effects of PlGF genetic ablation on myocardial fibrosis, finding that, although the Picrosirius Red-positive area in WT hearts increased in 1-week TAC, it was not significantly higher than baseline in KO ( Figure 3A and 3B). Furthermore, transcription of collagen-I, collagen-III, and fibronectin, 3 extracellular matrix components typically overexpressed during TAC, was strongly increased in WT but not in KO ( Figure 3C through 3E).
Myocardial fibrosis is due in large part to the inflammatory response established during TAC; interestingly, PlGF is at the same time a cytokine with attractive properties for myelomonocytic cells and a permeability factor. 22 We found that lack of PlGF impaired the activation of vessel permeability induced by TAC in WT ( Figure 1A ) and negatively affected recruitment of CD68-positive monocytes in response to TAC ( Figure 4B) . Accordingly, the expression pattern of typical proinflammatory and antiinflammatory mediators (interleukin-1␣, interleukin-1␤, TNF-␣ and transforming growth factor-␤) was completely altered in a time-dependent fashion in the absence of PlGF ( Figure 4C through 4F). In particular, the lack of PlGF abolished interleukin-1␣ ( Figure 4C ), TNF-␣ ( Figure 4E ), and transforming growth factor-␤ ( Figure 4F ) during the first early wave (6 hours) of upregulation induced by TAC and normalized after 3 days. Interestingly, 1 week after TAC, these cytokines showed a second wave of increase ( Figure 4C , 4E, and 4F), accompanied by interleukin-1␤ upregulation ( Figure 4D ) in WT, whereas a still impaired response was observed in KO ( Figure  4C through 4F). Overall, these results indicate that KO failed to establish an early inflammatory response to TAC and to control it over time.
Matrix metalloproteinases (MMPs) and their inhibitors are known to orchestrate the onset of inflammation during a tissue challenge by regulating cytokine bioavailability in the microenvironment. Thus, the cardiac expression profile of selected extracellular matrix structural constituents, proteases and proteases inhibitors, was performed with a polymerase chain reaction array. Only TIMP-3 was significantly upregulated in KO but not in WT after TAC. On the other hand, among the MMP genes evaluated, MMP-10, MMP -7, and MMP -8 expression increased only in WT but not in KO overloaded hearts (Table IV in the online-only Data Supplement). 
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PlGF, Cardiac Inflammation, and Remodeling of the main regulators of extracellular matrix proteases activation, TACE, is critically required for the occurrence of TNF-␣ release in its active soluble form.
To better clarify the PlGF effect on TNF-␣, we measured the amount of active soluble TNF-␣ early after TAC (at 1 day) and then at 1 week. We found that KO had TNF-␣ levels almost equal to those of sham, whereas WT showed an early and consistent TNF-␣ increase ( Figure 5A ). Then, we evaluated TACE activity, finding that in WT TAC was able to rapidly activate TACE (at 1 day) and maintain its activation over time (1 week) ( Figure 5B ). Conversely, KO mice were unable to induce TACE ( Figure 5B ), thus indicating that PlGF is able and indispensable to condition TACE activation. Interestingly, double staining for TACE and the main cellular types involved in cardiac remodeling revealed that resident cells like cardiomyocytes ( Figure 5C ) and vessels ( Figure  5D Recruitment of the TACE pathway also induces a process of regulated intramembrane proteolysis, affecting a wide variety of transmembrane proteins. 23 Interestingly, analysis of membrane and soluble fractions from overloaded heart homogenates revealed the processing of VEGFR-1, forming the 2 soluble fragments, a cytosolic 80-kDa fragment and an extracellular 120-kDa fragment, only in WT but not in KO ( Figure 5C ). Similarly, KO failed to activate the TACEinduced Notch-1 pathway, hampering NICD formation (Figure 5D ) and the consequent upregulation of the transcription factor Hes-1 ( Figure 5E ). Therefore, KO showed an impaired proteolytic processing that was dependent on TACE activity, further supporting that PlGF is crucial to permit the cascade of molecular events leading to TACE activation in response to TAC. Further supporting a failure in activating TACE pathway, KO did not show TAC-induced activity of MMP-2, a typical MMP downstream of TACE, as evidenced by gelatin zymographic analysis ( Figure 5F ).
Finally, we treated WT during TAC with TAPI-I, an inhibitor of TACE activity, to see whether this strategy reproduced the phenotypic traits displayed by KO. Noticeably, we found a cardiac response to TAC similar to that previously observed in KO. In particular, echocardiographic analysis revealed impaired hypertrophic response (as shown by relative wall thickness and LV internal diameter in Figure 6A and 6B) and cardiac function (fractional shortening; Figure 6C ), accompanied by increased vessel dimensions ( Figure 6D and 6E ).
Placental Growth Factor Is Indispensable in Keeping Normal Cardiac Tissue Inhibitor of Metalloproteinases-3 Expression Levels During Transverse Aortic Constriction, Allowing the Establishment of Adaptive Left Ventricular Hypertrophic Response With Fully Retained Cardiac Function
Intriguingly, we revealed by polymerase chain reaction array analysis ( Table III in the online-only Data Supplement) and by Western blot that TIMP-3, the main negative regulator of TACE activity, was strongly upregulated in KO during TAC starting early at 1 day ( Figure 7A) and was sustained at 1 week ( Figure IIIA in the online-only Data Supplement), whereas it remained unmodified in WT. Actually, it has been reported that TIMP-3 is upregulated by TAC later, ie, at 3 weeks, 16 probably to dampen the ongoing inflammatory response. Our unexpected result suggested that PlGF could have a role in maintaining normal TIMP-3 expression levels, known to be important in balancing TACE activation. To prove that PlGF directly regulates TIMP-3 expression, we treated PlGF KO mice with recombinant PlGF. As shown in Figure 7B , PlGF treatment was able to restore TIMP-3 expression to normal levels during TAC, thus demonstrating a direct dependence of TIMP-3 on PlGF. Because TIMP-3 is a protein secreted in the extracellular matrix and its regulation is mainly at the transcriptional level, we used the in situ hybridization technique to confirm and localize the increased expression of TIMP-3 at the mRNA level. As shown in Figure 7C , TAC induced an increased staining for TIMP-3 mRNA in KO compared with WT. Both cardiomyocytes (red arrow) and vessels (red arrowheads) were intensely stained ( Figure 7C ).
Thus, we looked for a strategy to normalize early TIMP-3 overexpression in KO by interfering at transcriptional level. To this aim, we used an in vivo silencing approach by systemically administering a small interfering RNA (siRNA) in KO. We first proved the efficacy of this approach in our model by administering a control siRNA-FITC to visualize its delivery in cardiac tissue by histology ( Figure 7D ).
We started siRNA administration for both TIMP-3 and negative control 3 days before TAC, repeating the treatment every 5 days. Western blot analysis revealed that only siRNA for TIMP-3 was able to reduce the cardiac TIMP-3 protein levels of KO, starting at 1-day TAC ( Figure IIIA in the online-only Data Supplement). The effect was even more marked at 1-week TAC ( Figure 7E and Figure IIIA in the online-only Data Supplement). Therefore, this siRNA-based strategy allowed a reduction in the abnormal TIMP-3 protein levels observed in KO in response to TAC ( Figure 7E ) and a restored activation of TACE ( Figure 7F Figure 8A and 8B) and retained cardiac function (fractional shortening; Figure 8C ) in response to TAC, whereas negative control KO still displayed eccentric hypertrophic remodeling ( Figure 8A and 8B) and cardiac dysfunction ( Figure 8C ) after TAC.
At histological evaluation, wheat germ agglutinin and isolectin staining revealed that TIMP-3 siRNA rescued TACinduced cardiomyocyte growth ( Figure 8D and 8E) and restored vessel dimensions ( Figure 8D and 8F) in KO compared with negative control siRNA. Finally, the CD68positive staining found in TIMP-3 siRNA KO also indicated a rescue of the inflammatory component in response to TAC ( Figure 8G ). Together, these results demonstrate that targeting TIMP-3 levels rescues the inflammatory adaptive response to hemodynamic overload, allowing a proper LV myocyte and vascular remodeling in KO.
Discussion
In this study, we identify PlGF as an indispensable component of the cardiac response to pressure overload because its ablation hampered the development of typical compensatory hypertrophy, hastening the transition toward dilated cardiomyopathy and heart failure. In particular, the lack of PlGF induced an impaired cardiomyocyte growth with increased vessel dimensions. These features of cardiac remodeling in KO were accompanied by an impaired inflammatory response and the development of LV fibrosis. Dissection of molecular mechanisms highlighted a regulating role of PlGF on TACE, a key molecule of tissue inflammatory response recently identified as a master regulator in cardiac hypertrophic remodeling. 5 We found that PlGF is necessary to maintain normal levels of cardiac TIMP-3, the TACE natural inhibitor, allowing early TACE activation and consequently TNF-␣ production during TAC. Strikingly, the decrease in TIMP-3 levels with an siRNA approach rescued early dilated cardiomyopathy and cardiac dysfunction.
The deterioration of cardiac structure and function displayed by KO in response to hemodynamic overload was demonstrated by conventional and strain-based echocardio- Overall, this phenotype seems to recapitulate traits observed during inhibition of other angiogenic factors like endogenous VEGF. 6 In particular, VEGF sequestering with Flk-1 ectodomain similarly impaired adaptive cardiac hypertrophy with accelerated transition to heart failure. 6 In this case, the impairment of cardiac hypertrophic response was due to a marked reduction in coronary capillary density. On the contrary, our data indicate that, even if the absence of PlGF hampers compensatory LVH response to TAC, this phenotype should be ascribed to factors others than capillary rarefaction. Actually, KO mice display a vascular remodeling with greater capillary dimensions than those observed in WT mice. Such a condition ensures an improved myocardial perfusion during TAC, thus preserving cardiac tissue from hypoxia. Moreover, TAC-induced myocardial interstitial fibrosis, markedly increased in VEGF deprivation, was conversely reduced in KO, suggesting that the deterioration of cardiac structure and function developed by overloaded KO has to be ascribed mainly to a defect in adaptive muscle growth, because both myocardial perfusion and interstitial fibrosis responses could have been traits leading to a more favorable fate. However, our analysis with recombinant PlGF excluded a direct effect of PlGF on cardiomyocyte growth, suggesting that the adverse cardiac remodeling in KO should recruit other mechanisms.
On this topic, it is noteworthy to emphasize that KO markedly showed reduced monocyte recruitment in overloaded hearts and failed to upregulate expression of typical inflammatory cytokines. Furthermore, during TAC, the lack of PlGF impaired the cardiac release of active TNF-␣, a cytokine with a great impact on LV remodeling 5 recently associated with the effect of PlGF on myelomonocytic cell recruitment to the inflamed tissue. 14 This picture is strongly supportive of a key role of PlGF in establishing an adequate and necessary inflammatory response to TAC. The reduced TNF-␣ levels in KO were dependent on an impaired activity of TACE, a pivotal regulator of TNF-␣ release and newly identified player in cardiac remodeling resulting from TAC. 5 Besides TNF-␣, TACE activation is critically required for the occurrence of cleavage of other proteolytic substrates. As further support of the role of PlGF in activating TACE during TAC, we found that other shedding products were formed only in WT and not in KO. Among them, we proposed 2 proteins that could be potentially relevant during TAC. One is sVEGFR-1, derived by the full-length receptor of PlGF (VEGFR-1); the other is Notch-1, which, after shedding, forms an intracellular fragment called NICD with transcriptional functions. Interestingly, it has recently been demonstrated that a VEGFR-1 shedding product can have antiangiogenic properties at least in vitro, 24, 25 in accordance with our finding that inhibition of PlGF and thus of its receptor processing has growth function on microvasculature. In addition, well-established knowledge clearly shows that Notch-1 inhibition has proangiogenic properties. 26 -28 On the whole, this strongly points to an important upstream role of PlGF-induced TACE activation during cardiac response to TAC. Furthermore, our results that pharmacological TACE inhibition displayed impaired LVH remodeling and increased vessel dimensions in response to TAC, resembling those previously observed in KO, strongly support that PlGF regulates tissue remodeling by controlling TACE activity.
Typically, the process involving the proteolytic cleavage of substrates is a noncell autonomous mechanism, always requiring the contact of a cell presenting the substrate and another with the protease (TACE in this case). The involvement of a noncell autonomous mechanism is further supported by the evidence that TACE was localized both in resident cells such as cardiomyocytes and vessels and in inflammatory cells. Thus, because VEGFR-1 is expressed by resident cardiac cells like endothelium and cardiomyocytes and circulating cells like monocytes, PlGF could orchestrate the complex cardiac remodeling by acting on all of these cell types. Interestingly, we identified that expression of TIMP-3, the only extracellular matrix-bound TIMP known to check inflammation through inhibition of TACE 29 with recognized functions during TAC-induced cardiac remodeling, 15, 16 was significantly increased in KO after TAC, whereas it remained unchanged in WT. With in situ hybridization, we found that the increased mRNA expression was present mainly in vessels and cardiomyocytes, both known to express PlGF receptor and involved in the maladaptive remodeling observed in KO.
Strikingly, when we used an siRNA approach to reduce TIMP-3 expression to normal levels during TAC in KO, we found a complete phenotype rescue at echocardiographic analysis, hampering the early transition toward dilated cardiomyopathy. The histological examination revealed a rescue of cardiac hypertrophy and monocyte recruitment, as well as a restoration of vessel dimensions. The reactivation of TACE in KO treated with TIMP-3 siRNA suggests that TIMP-3 is the primary target of PlGF. Therefore, it emerges that the TIMP-3/TACE axis must be tightly balanced during an inflammatory response and in cardiac TAC. Only this balance allows the establishment of an LVH response and correct matrix remodeling on TAC, both indispensable to compensate for stress on cardiac walls and to delay the transition to heart failure.
On this topic, it is noteworthy to mention that Kassiri et al 16 demonstrated that TAC is able to induce transcriptional regulation of TIMP-3 but only after 3 weeks after TAC, likely to check the already activated inflammatory response. Here, we show that in the absence of PlGF, the increased expression of TIMP-3 turns out to be an earlier event, hampering the establishment of inflammatory response. Thus, during TAC, PlGF is crucial to retain balanced cardiac TIMP-3 levels.
Our results seem to conflict with previous data showing that TIMP-3 KO, obtained by embryonic knockdown of the gene, led to natural deterioration of cardiac structure and function with aging 30 and accelerated transition to heart failure on TAC. 16 These effects were ascribed mainly to a dysregulated TACE activation and excessive cytokine production, leading to exacerbated inflammation, fibrosis, and hypertrophy and recognizing that maladaptive matrix remodeling promotes abnormal cardiac structure and function. 16 However, our approach, based on in vivo siRNA, was able to target TIMP-3 expression in just a specific time window, thus probably avoiding the deleterious effect of a complete lack of this important regulator of tissue remodeling. Our results demonstrate that the establishment of an early balanced inflammatory response during TAC is necessary for a compensatory hypertrophic response, retaining cardiac function.
Finally, it is of note in the upcoming evidence that, besides the already-mentioned downstream targets of the TIMP-3/ TACE axis, some specific MMPs have recently been identified as being involved in the development of compensatory LVH response to TAC. Among them, we found that typical TAC-induced MMP-2 activation 31 was impaired in KO.
Taken together, our results and those from previous studies demonstrate that the balance between TIMP-3 and TACE is pivotal in LV response to injury and provide insight into novel therapeutic strategies that should be taken into account to limit adverse remodeling during the onset of heart failure.
A potential limitation of our study is the use of a germline KO model that does not allow a temporal and/or spatial selectivity of intervention on PlGF expression. Selective ablation of PlGF in each of the cell types involved would allow us to clearly distinguish the contribution of PlGF signaling in cardiomyocytes, endothelium, and monocytes. Work is underway on this issue.
Conclusions
We identify a novel function of PlGF as a regulator of TIMP-3/TACE axis during cardiac remodeling in response to TAC. In particular, our data support a role for PlGF in exerting a transcriptional regulation of TIMP-3 to tightly check inflammation.
This finding arouses important questions of potential clinical remark. One interesting point is about the clinical impact of therapeutic applications of anti-PlGF antibodies. Clinical studies have indeed shown that PlGF levels correlate with poor prognosis in various cancer forms, and consequently, anti-PlGF monoclonal antibodies have been developed as a strategy to slow tumor growth. 9, 10 Besides the discrepancies among different evidence reported about the efficacy of tumor therapies exploiting anti-PlGF antibodies, 9, 10 this novel role of PlGF in cardiac remodeling makes further consideration necessary when deciding on this therapy in patients with increased cardiovascular risk.
